Payment overview · 2025
General Payments
$474.10
15 reported records · 8 companies
Healthcare provider profile · identity verified
Manish Kumar Mishra, M.D
Allopathic & Osteopathic Physicians|Family Medicine · POTTSVILLE, PA · NPI 1306089222
Verified facts
What the public records show
CMS Open Payments records show Manish Kumar Mishra, M.D received $474.10 in general payments during 2025 across 15 reported records.
AstraZeneca Pharmaceuticals LP accounted for 42.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 263 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1567 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $198.99 | 42.0% | 5 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $104.04 | 21.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $38.48 | 8.1% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.42 | 7.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $36.32 | 7.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $23.58 | 5.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.42 | 4.3% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $15.85 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $474.10 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $198.99 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $38.48 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $38.48 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $36.42 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $36.32 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $36.32 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $23.58 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $15.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 263 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 136 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
43 | 13 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
86 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
263 | 40 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
136 | 34 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
30 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1567 | 119 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 3313 | 339 |
| Amlodipine Besylate | Amlodipine Besylate | 1739 | 173 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1728 | 163 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1718 | 191 |
| Metoprolol Succinate | Metoprolol Succinate | 1603 | 167 |
| Eliquis | Apixaban | 1567 | 119 |
| Gabapentin | Gabapentin | 1503 | 140 |
| Furosemide | Furosemide | 1338 | 136 |
| Tamsulosin Hcl | Tamsulosin Hcl | 1224 | 84 |
| Potassium Chloride | Potassium Chloride | 1166 | 99 |
| Lisinopril | Lisinopril | 1117 | 124 |
| Sertraline Hcl | Sertraline Hcl | 1064 | 76 |
| Clopidogrel | Clopidogrel Bisulfate | 943 | 77 |
| Divalproex Sodium | Divalproex Sodium | 856 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 742 | 44 |
| Mirtazapine | Mirtazapine | 705 | 64 |
| Trazodone Hcl | Trazodone Hcl | 685 | 64 |
| Metoprolol Tartrate | Metoprolol Tartrate | 684 | 94 |
| Metformin Hcl | Metformin Hcl | 659 | 88 |
| Escitalopram Oxalate | Escitalopram Oxalate | 648 | 50 |
| Buspirone Hcl | Buspirone Hcl | 617 | 69 |
| Carvedilol | Carvedilol | 607 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 606 | 63 |
| Losartan Potassium | Losartan Potassium | 522 | 87 |
| Torsemide | Torsemide | 518 | 51 |
| Omeprazole | Omeprazole | 497 | 100 |
| Allopurinol | Allopurinol | 479 | 51 |
| Levetiracetam | Levetiracetam | 459 | 28 |
| Famotidine | Famotidine | 446 | 57 |
| Simvastatin | Simvastatin | 400 | 58 |
| Donepezil Hcl | Donepezil Hcl | 390 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 382 | 36 |
| Warfarin Sodium | Warfarin Sodium | 348 | 26 |
| Olanzapine | Olanzapine | 340 | 25 |
| Januvia | Sitagliptin Phosphate | 324 | 25 |
| Memantine Hcl | Memantine Hcl | 316 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 308 | 24 |
| Lamotrigine | Lamotrigine | 304 | 14 |
| Montelukast Sodium | Montelukast Sodium | 283 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 273 | 50 |
| Jardiance | Empagliflozin | 263 | 40 |
| Risperidone | Risperidone | 258 | 17 |
| Myrbetriq | Mirabegron | 246 | 20 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 236 | 14 |
| Tramadol Hcl | Tramadol Hcl | 235 | 48 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 227 | 19 |
| Baclofen | Baclofen | 224 | suppressed |
| Rexulti | Brexpiprazole | 221 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 218 | 24 |
| Lorazepam | Lorazepam | 217 | 48 |
| Amiodarone Hcl | Amiodarone Hcl | 216 | 11 |
| Memantine Hcl Er | Memantine Hcl | 208 | 15 |
| Prednisone | Prednisone | 200 | 111 |
| Alprazolam | Alprazolam | 199 | 34 |
| Propranolol Hcl | Propranolol Hcl | 197 | suppressed |
| Xarelto | Rivaroxaban | 193 | 13 |
| Glipizide | Glipizide | 189 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 174 | 70 |
| Hydrochlorothiazide | Hydrochlorothiazide | 173 | 26 |
| Tradjenta | Linagliptin | 172 | 16 |
| Spironolactone | Spironolactone | 167 | 17 |
| Ezetimibe | Ezetimibe | 164 | 29 |
| Atenolol | Atenolol | 162 | 23 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 160 | 38 |
| Finasteride | Finasteride | 159 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 153 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 151 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 144 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 144 | 12 |
| Ozempic | Semaglutide | 136 | 34 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 132 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 129 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 129 | 16 |
| Aripiprazole | Aripiprazole | 125 | 13 |
| Glimepiride | Glimepiride | 125 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 125 | 26 |
| Oxybutynin Chloride | Oxybutynin Chloride | 122 | suppressed |
| Topiramate | Topiramate | 118 | suppressed |
| Digoxin | Digoxin | 116 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 114 | 47 |
| Alendronate Sodium | Alendronate Sodium | 109 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 106 | suppressed |
| Nifedipine Er | Nifedipine | 102 | suppressed |
| Amoxicillin | Amoxicillin | 101 | 87 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 100 | 59 |
| Azithromycin | Azithromycin | 93 | 74 |
| Fenofibrate | Fenofibrate | 92 | 11 |
| Lacosamide | Lacosamide | 91 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 90 | 11 |
| Benztropine Mesylate | Benztropine Mesylate | 86 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 86 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 85 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 82 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 81 | 19 |
| Gemtesa | Vibegron | 80 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 80 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 80 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 79 | 51 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 78 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 78 | suppressed |
| Nystatin | Nystatin | 77 | 33 |
| Sucralfate | Sucralfate | 77 | 12 |
| Meloxicam | Meloxicam | 75 | 40 |
| Doxycycline Hyclate | Doxycycline Hyclate | 74 | 44 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 73 | 33 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 72 | 13 |
| Valsartan | Valsartan | 72 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 71 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 71 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 67 | 16 |
| Fenofibrate | Fenofibrate,micronized | 66 | suppressed |
| Cephalexin | Cephalexin | 65 | 44 |
| Clonazepam | Clonazepam | 65 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 65 | suppressed |
| Lansoprazole | Lansoprazole | 62 | 13 |
| Enalapril Maleate | Enalapril Maleate | 61 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | 13 |
| Cholestyramine | Cholestyramine (With Sugar) | 60 | 29 |
| Midodrine Hcl | Midodrine Hcl | 59 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 59 | suppressed |
| Scopolamine | Scopolamine | 59 | suppressed |
| Glipizide Er | Glipizide | 58 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 58 | 26 |
| Latanoprost | Latanoprost | 56 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 17 |
| Trulicity | Dulaglutide | 55 | 11 |
| Chlorthalidone | Chlorthalidone | 54 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 54 | suppressed |
| Lactulose | Lactulose | 54 | suppressed |
| Nitroglycerin | Nitroglycerin | 54 | 43 |
| Carbamazepine Er | Carbamazepine | 53 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 42 |
| Atomoxetine Hcl | Atomoxetine Hcl | 52 | suppressed |
| Captopril | Captopril | 52 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 52 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 52 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 52 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 51 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 11 |
| Selegiline Hcl | Selegiline Hcl | 51 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 51 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 49 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 49 | 12 |
| Novolog Flexpen | Insulin Aspart | 49 | 17 |
| Methimazole | Methimazole | 48 | suppressed |
| Ketoconazole | Ketoconazole | 47 | 16 |
| Olanzapine-Fluoxetine Hcl | Olanzapine/Fluoxetine Hcl | 47 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 46 | suppressed |
| Bupropion Xl | Bupropion Hcl | 45 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 45 | 32 |
| Oxycodone Hcl | Oxycodone Hcl | 45 | 21 |
| Pregabalin | Pregabalin | 44 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 43 | suppressed |
| Cimetidine | Cimetidine | 43 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 43 | 42 |
| Synthroid | Levothyroxine Sodium | 43 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 42 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 42 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 41 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 40 | 22 |
| Celecoxib | Celecoxib | 39 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 39 | suppressed |
| Anastrozole | Anastrozole | 38 | suppressed |
| Diazepam | Diazepam | 38 | suppressed |
| Carbamazepine | Carbamazepine | 37 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 36 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 35 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 35 | suppressed |
| Levofloxacin | Levofloxacin | 35 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | suppressed |
| Novolog | Insulin Aspart | 35 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 34 | 12 |
| Pilocarpine Hcl | Pilocarpine Hcl | 34 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 34 | 25 |
| Ceftriaxone | Ceftriaxone Sodium | 33 | 20 |
| Entresto | Sacubitril/Valsartan | 33 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 33 | suppressed |
| Secuado | Asenapine | 33 | suppressed |
| Metolazone | Metolazone | 32 | suppressed |
| Sulfasalazine | Sulfasalazine | 32 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 31 | suppressed |
| Hydrocortisone | Hydrocortisone | 31 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 30 | 30 |
| Primidone | Primidone | 30 | suppressed |
| Timolol Maleate | Timolol Maleate | 30 | suppressed |
| Rytary | Carbidopa/Levodopa | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 22 |
| Spiriva Respimat | Tiotropium Bromide | 28 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 27 | suppressed |
| Ethosuximide | Ethosuximide | 27 | suppressed |
| Levemir Flexpen | Insulin Detemir | 27 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 27 | 16 |
| Ofloxacin | Ofloxacin | 27 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 26 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 26 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 24 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 23 | 19 |
| Megestrol Acetate | Megestrol Acetate | 23 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 22 | suppressed |
| Jantoven | Warfarin Sodium | 22 | suppressed |
| Nyamyc | Nystatin | 22 | 15 |
| Raloxifene Hcl | Raloxifene Hcl | 22 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 21 | suppressed |
| Dextrose 5%-0.9% Nacl | Dextrose 5 % And 0.9 % Nacl | 21 | 12 |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Metronidazole | Metronidazole | 21 | 14 |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 20 | suppressed |
| Colchicine | Colchicine | 20 | 11 |
| Humalog | Insulin Lispro | 20 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 19 | 11 |
| Fluconazole | Fluconazole | 19 | 13 |
| Ursodiol | Ursodiol | 19 | suppressed |
| Glucagon Emergency Kit | Glucagon | 18 | suppressed |
| Peg-3350 And Electrolytes | Peg3350/Sod Sulf,bicarb,cl/Kcl | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | suppressed |
| Erythromycin | Erythromycin Base | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Valganciclovir Hcl | Valganciclovir Hcl | 17 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Lubiprostone | Lubiprostone | 16 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 14 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 13 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 13 | suppressed |
| Restasis | Cyclosporine | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 12 | 11 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Phenytek | Phenytoin Sodium Extended | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 11 | suppressed |
| Cholestyramine Light | Cholestyramine | 11 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 11 | suppressed |
| Methylprednisolone Acetate | Methylprednisolone Acetate | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Ramipril | Ramipril | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $474.10 · 15 records | AstraZeneca Pharmaceuticals LP | AUSTEDO XR, EVENITY, JARDIANCE, LOKELMA, Ozempic, QULIPTA, Rybelsus, UBRELVY, VYNDAMAX | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error